l General Information |
Product Name | Carbidopa Monohydrate |
General description | Carbidopa is an Aromatic Amino Acid Decarboxylation Inhibitor, preventing conversion of levodopa to dopamine. |
Synonym | (S)-3-(3,4-Dihydroxyphenyl)-2-hydrazino-2-methylpropionic acid monohydrate; Carbidopa hydrate; Carbidopa Monohydrate; |
Purity | ≥98%(HPLC) | CAS Number | 38821-49-7 |
Formula | C10H14N2O4 · H2O | Molecular Weight | 244.24 |
Suitability | BioReagent, suitable for cell culture, etc. |
l Physical and Chemical Information |
Appearance | White or Off-white solid |
Solubility(25℃) | DMSO | ~0.01mg/mL |
Ethanol | Insoluble |
Water | Insoluble |
l Biological Information |
Biochem/Physiol Actions | Carbidopa is a hydrazine derivative of dopa. Carbidopa is a peripheral dopa decarboxylase inhibitor that is used as an adjunct to levodopa administration to prevent peripheral biosynthesis of levodopa to dopamine, thereby reducing peripheral side effects. Carbidopa does not penetrate the blood brain barrier so that levodopa, after it reaches the brain, can be metabolized to dopamine by dopa decarboxylase where it exerts its effect on dopamine receptors. |
Application | 1. Antiparkinson Agents 2. Dopamine Agents 3. Aromatic Amino Acid Decarboxylase Inhibitors |
l Packaging & Storage |
Packaging | 1g |
Storage temp. | 0-5℃ |
l Precautions and Disclaimer |
This product is for R&D use only, not for drug, household, or other uses. |
l References |
1. http://www.drugbank.ca 2. https://ncit.nci.nih.gov 3. https://www.ncbi.nlm.nih.gov |
